Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Leap Therapeutics, Inc. (CYPH) had Return on Tangible Equity of -122.56% for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-3.30M |
|
-- |
|
-- |
|
$3.17M |
|
$-3.17M |
|
$0.07M |
|
$-3.10M |
|
$-3.10M |
|
$-3.30M |
|
$-3.30M |
|
$-3.30M |
|
$-3.30M |
|
$-3.17M |
|
$-3.17M |
|
41.45M |
|
41.45M |
|
$-0.08 |
|
$-0.08 |
|
| Balance Sheet Financials | |
$10.50M |
|
-- |
|
$0.90M |
|
$11.40M |
|
$8.70M |
|
-- |
|
-- |
|
$8.70M |
|
$2.69M |
|
$2.69M |
|
$2.69M |
|
41.44M |
|
| Cash Flow Statement Financials | |
$-37.28M |
|
-- |
|
$-0.30M |
|
$47.25M |
|
$9.69M |
|
$-37.56M |
|
$3.00M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.21 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-37.28M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-122.56% |
|
|
Return on Tangible Equity |
-122.56% |
-28.98% |
|
-122.56% |
|
$0.07 |
|
$-0.90 |
|
$-0.90 |
|